UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 41 filers reported holding UROGEN PHARMA LTD in Q4 2017. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $28,000 | – | 3,047 | +6383.0% | 0.00% | – |
Q4 2021 | $0 | -100.0% | 47 | 0.0% | 0.00% | – |
Q3 2021 | $1,000 | 0.0% | 47 | 0.0% | 0.00% | – |
Q2 2021 | $1,000 | -97.5% | 47 | -97.7% | 0.00% | -100.0% |
Q1 2021 | $40,000 | +100.0% | 2,047 | +85.6% | 0.00% | +100.0% |
Q4 2020 | $20,000 | -59.2% | 1,103 | -56.7% | 0.00% | -66.7% |
Q3 2020 | $49,000 | +81.5% | 2,547 | +143.3% | 0.00% | +50.0% |
Q2 2020 | $27,000 | -70.0% | 1,047 | -61.2% | 0.00% | -71.4% |
Q4 2019 | $90,000 | +150.0% | 2,700 | +80.0% | 0.01% | +133.3% |
Q3 2019 | $36,000 | -2.7% | 1,500 | +50.0% | 0.00% | -25.0% |
Q1 2019 | $37,000 | -14.0% | 1,000 | 0.0% | 0.00% | -33.3% |
Q4 2018 | $43,000 | +79.2% | 1,000 | +100.0% | 0.01% | +100.0% |
Q3 2018 | $24,000 | -75.8% | 500 | -75.0% | 0.00% | -78.6% |
Q2 2018 | $99,000 | +120.0% | 2,000 | +122.2% | 0.01% | +100.0% |
Q1 2018 | $45,000 | +50.0% | 900 | +12.5% | 0.01% | +40.0% |
Q4 2017 | $30,000 | -14.3% | 800 | 0.0% | 0.01% | -16.7% |
Q3 2017 | $35,000 | – | 800 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Horton Capital Management, LLC | 684,749 | $11,517,000 | 23.27% |
GREAT POINT PARTNERS LLC | 750,000 | $12,615,000 | 2.94% |
HealthInvest Partners AB | 75,000 | $1,262,000 | 1.89% |
Wildcat Capital Management, LLC | 533,139 | $8,967,000 | 1.16% |
Annandale Capital, LLC | 86,254 | $1,451,000 | 0.87% |
MENORA MIVTACHIM HOLDINGS LTD. | 2,954,699 | $49,698,000 | 0.73% |
ZEKE CAPITAL ADVISORS, LLC | 723,677 | $12,172,000 | 0.70% |
Yahav Achim Ve Achayot - Provident Funds Management Co Ltd. | 25,330 | $426,000 | 0.34% |
RTW INVESTMENTS, LP | 857,464 | $14,423,000 | 0.22% |
SHIKIAR ASSET MANAGEMENT INC | 33,350 | $561,000 | 0.16% |